BETHLEHEM, Pa., June 19, 2013 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing novel diagnostic tests that help physicians to optimize a patient's exposure to chemotherapy, today announced the U.S. launch of the MyCare™ portfolio of exposure optimization tests. The MyCare portfolio is comprised of simple blood tests that provide oncologists with specific information about each patient's exposure to chemotherapy, to help the doctor make informed decisions on drug dose adjustments, with the goals of maximizing the therapy's effectiveness and limiting its potential side effects. Saladax Biomedical Laboratories (SBL) will manage the commercialization and clinical laboratory operations for the MyCare portfolio of products at its CLIA-certified facility located in Bethlehem, PA.
"The launch of Saladax's MyCare tests in the U.S. represents an important advancement for oncologists and their patients in the fight against cancer," said Kevin M. Harter, CEO and President at Saladax Biomedical, Inc. "MyCare laboratory tests give oncologists the ability to measure how much exposure to chemotherapy an individual patient is experiencing. Exposure to too much drug results in higher frequency of toxicity in the patient, while exposure to too little drug can allow a cancer to grow more rapidly. Saladax's MyCare tests are designed to help a doctor make more informed treatment decisions based on objective measurements of drug exposure."
SBL's initial test menu offering is focused on three chemotherapy exposure optimization tests; MyPaclitaxel™, MyDocetaxel™ and also My5-FU™, which is currently marketed under the trade name OnDose® and being transitioned from Myriad Genetic Laboratories. A description of the three MyCare tests being launched today is as follows:
My5-FU - A simple blood test used to measure and help optimize a patient's exposure to 5-Fluorouracil (5-FU) therapy; a chemotherapy commonly used in the treatment of colorectal, breast, and head and neck cancers.
MyPaclitaxel - A simple blood test used to measure and help optimize a patient's exposure to paclitaxel therapy; a chemotherapy commonly used in the treatment of breast, non-small cell lung cancer (NSCLC), ovarian and digestive tract cancers.
MyDocetaxel - A simple blood test used to help measure and help optimize a patient's exposure to docetaxel therapy; a chemotherapy commonly used in the treatment of breast cancer, as well as non-small cell lung cancer (NSCLC), digestive tract, prostate and head & neck cancers.
Saladax Biomedical recently announced that the Centers for Medicare & Medicaid Services Office of Clinical Standards and Quality (OCSQ) certified SBL as a registered CLIA Laboratory. The certification allows SBL to run clinical laboratory operations for the MyCare portfolio at its facility located in Bethlehem, PA.
SBL anticipates expanding its menu of testing services to include more than a dozen new chemotherapy exposure optimization tests that Saladax Biomedical is currently developing.
About Saladax Biomedical, Inc.
Saladax Biomedical is a leader in the development and deployment of high-quality diagnostic services and products, delivering actionable data to help physicians to select and optimize the use of current and new pharmaceutical products, with the goals of improving health and positively impacting the economics of care… because no two patients are alike.
The company's proprietary MyCare™ exposure optimization tests are designed to improve the efficacy of existing drugs by helping physicians make informed decisions on drug dose adjustments for each individual patient. The initial focus of Saladax is oncology, with a portfolio of 13 chemotherapy drug assays in various stages of development. The initial portfolio of three MyCare exposure optimization tests is currently offered to the oncology community in markets around the world.
Headquartered in Bethlehem, Pennsylvania, Saladax was founded in 2004 and is ISO 13485:2003 certified. www.saladax.com
Saladax Biomedical, Inc.
Lorraine Damico, MBA
Director of Worldwide Marketing
SOURCE Saladax Biomedical, Inc.